1. Search Result
Search Result
Results for "

synaptic

" in MedChemExpress (MCE) Product Catalog:

142

Inhibitors & Agonists

1

Screening Libraries

4

Fluorescent Dye

21

Peptides

27

Natural
Products

4

Recombinant Proteins

7

Isotope-Labeled Compounds

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113995

    AH5183

    mAChR Neurological Disease
    (-)-Vesamicol (AH5183) is an inhibitor of acetylcholine transport into synaptic vesicles, with the IC50 of 75 nM . (-)-Vesamicol can be used for release and recycling of synaptic vesicles study .
    (-)-Vesamicol
  • HY-157999

    Synaptic Vesicle Proteins Neurological Disease
    SDI-118 is an orally active modulator for synaptic vesicle glycoprotein 2A (SV2A) with an IC50 of 13 nM .
    SDI-118
  • HY-107498

    iGluR Neurological Disease
    GNE-8324 is a selective GluN2A positive allosteric modulator. GNE-8324 selectively enhances NMDA receptor (NMDAR)-mediated synaptic responses in inhibitory but not excitatory neurons .
    GNE-8324
  • HY-D1438

    Fluorescent Dye Others
    RH 414 is the styryl pyridinium dye. RH 414 can be used for optical monitoring of synaptic vesicle membrane trafficking .
    RH 414
  • HY-B0649
    Propofol
    10+ Cited Publications

    2,6-Diisopropylphenol

    GABA Receptor Endogenous Metabolite Neurological Disease Cancer
    Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic .
    Propofol
  • HY-145761

    iGluR Neurological Disease
    AMPA-IN-1 is a potent inhibitor of AMPA receptor. AMPA receptors are receptors that are widely expressed in the brain, and play a central role in the regulation of fast excitatory synaptic transmission and synaptic plasticity. AMPA-IN-1 has the potential for the research of various central diseases including epilepsy (extracted from patent WO2017082288A1, compound 14) .
    AMPA-IN-1
  • HY-D1516

    Fluorescent Dye Others
    NerveGreen C3 is a cationic styrene based fluorescent dye. NerveGreen C3 can be used to track synaptic activity at neuromuscular junctions or synapses .
    NerveGreen C3
  • HY-121318

    Adrenergic Receptor Neurological Disease
    LK-11 is a tropane derivative that inhibits the passive uptake of noradrenalin (NA) by hypothalamic synaptic vesicles in vitro, similar to cocaine .
    LK 11
  • HY-100714B

    L-APV; L-2-Amino-5-phosphonovaleric acid

    iGluR Neurological Disease
    L-AP5 (L-APV; L-2-Amino-5-phosphonovaleric acid) is an NMDA antagonist and is the isomer of D-AP5 (HY-100714A). L-AP5 shows a relatively weak amino acid and synaptic blocking activity .
    L-AP5
  • HY-P3340

    iGluR Neurological Disease
    Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .
    Leptin (116-130)
  • HY-P0062

    SNX-111

    Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Ziconotide (SNX-111), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide
  • HY-P0062B

    SNX-111 acetate

    Calcium Channel Cardiovascular Disease Inflammation/Immunology Cancer
    Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide acetate
  • HY-W049881

    Dopamine Receptor Neurological Disease Inflammation/Immunology
    9-Methyl-β-carboline is a cognitive enhancer with neuroprotective, neurorestorative and anti-inflammatory properties. The behavioral effects of 9-Methyl-β-carboline may be related to the stimulation of hippocampal dopamine levels and dendritic and synaptic proliferation .
    9-Methyl-β-carboline
  • HY-P0062A

    SNX-111 TFA

    Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide TFA
  • HY-120051

    S44819; Egis-13529

    GABA Receptor Neurological Disease
    Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR, with an IC50 of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy .
    Afizagabar
  • HY-108497

    Somatostatin Receptor Neurological Disease Cancer
    L-803087 is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .
    L-803087
  • HY-145155
    Calpain-2-IN-1
    1 Publications Verification

    Proteasome Neurological Disease
    Calpain-2-IN-1 (Formula 1A) is a isoform-specific calpain-2 inhibitor with Kis of 181 nM and 7.8 nM for calpain-1, and calpain-2, respectively. Calpain-2-IN-1 can be used for the research of neurodegenerative diseases and other diseases of synaptic function .
    Calpain-2-IN-1
  • HY-108497A

    Somatostatin Receptor Neurological Disease Cancer
    L-803087 TFA is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM. L-803087 TFA is >280-fold more selective for sst4 receptor than other somatostatin receptors. L-803087 TFA facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .
    L-803087 TFA
  • HY-D1515

    Neurodye GH1-84

    Fluorescent Dye Neurological Disease
    FM1-84 (Neurodye GH1-84) is a fluorescent dye. FM1-84 has lipophilic and facilitates association with membranes, resulting in an increase in fluorescence intensity (λex=510 nm, λem=625 nm). FM1-84 can be used for synaptic vesicle recycling in neurons research .
    FM1-84
  • HY-102068

    HIV Infection
    Clathrin-IN-1 is a selective clathrin-mediated endocytosis (CME) inhibitor. Clathrin-IN-1 selectively inhibits amphiphysin association of clathrin terminal domain (TD) with an IC50 value of 12 μM. Clathrin-IN-1 acutely interferes with receptor-mediated endocytosis, entry of HIV, and synaptic vesicle recycling .
    Clathrin-IN-1
  • HY-100821

    Bacterial Infection
    2,4-Dihydroxyphenylacetylasparagine is a potent and selective antagonist of glutamate. 2,4-Dihydroxyphenylacetylasparagine inhibits glutamate binding to rat brain synaptic membranes .
    2,4-Dihydroxyphenylacetylasparagine
  • HY-P2259
    TAT-GluA2 3Y
    1 Publications Verification

    iGluR Neurological Disease
    TAT-GluA2 3Y, an interference peptide, blocks long-term depression (LTD) at glutamatergic synapses by disrupting the endocytosis of AMPAR. TAT-GluA2 3Y can alleviate Pentobarbital-induced spatial memory deficits and synaptic depression .
    TAT-GluA2 3Y
  • HY-B0106
    Levetiracetam
    1 Publications Verification

    UCB L059

    DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
    Levetiracetam
  • HY-162566

    Calcium Channel Amyloid-β Neurological Disease
    REM127 is a small molecule compound capable of modulating calcium homeostasis in cells and possesses neuroprotective effects. REM127 can restore the calcium homeostasis imbalance in cellular models caused by pathological accumulation of tau protein. REM127 can efficiently cross the blood-brain barrier, and it has the potential to rescue synaptic and cognitive deficits in Alzheimer's disease animal models, as well as to slow down the progression of amyloid-beta and tau protein pathologies. REM127 can be used for research in neurodegenerative diseases .
    REM127
  • HY-B0106R

    DNA Methyltransferase Neurological Disease Cancer
    Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
    Levetiracetam (Standard)
  • HY-156104

    PROTACs CaMK Neurological Disease
    CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .
    CaMKIIα-PHOTAC
  • HY-116377

    Steroid Sulfatase Neurological Disease
    DU-14 is a potent steroid sulfatase inhibitor with an IC50 of 55.8 nM. DU-14 inhibits the MCF-7 cell proliferation (IC50 = 38.7 nM). DU-14 has neuroprotective effects against neurotoxic Aβ, suggesting that up-regulation of endogenous DHEAS by DU-14 could be beneficial to the alleviation of Aβ-induced impairments in spatial memory and synaptic plasticity .
    DU-14
  • HY-112828

    DAGL Neurological Disease Metabolic Disease Inflammation/Immunology
    LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation .
    LEI105
  • HY-129408

    GABA Receptor Neurological Disease
    SGE-516 is a neuroactive steroid that is a potent positive allosteric modulator of synaptic and extra-synaptic GABAA receptors. SGE-516 has anticonvulsant activity .
    SGE-516
  • HY-107506

    mGluR Neurological Disease
    Ro 67-4853 is a positive allosteric modulator (PAM) of mGluR1 (pEC50=7.16 for rmGlu1a receptor). Ro67-4853 exhibits activity at all group I mGlu receptors including hmGlu1, rmGlu1, and rmGlu5. Ro 67-4853 enhances the potency of L-Glu by interacting with the transmembrane domain (TMD) of the receptor. Ro 67-4853 potentiates sensory synaptic responses to repetitive vibrissa stimulation .
    Ro 67-4853
  • HY-122487

    BHV-4157

    mGluR Neurological Disease Cancer
    Troriluzole, a third-generation, tripeptide proagent of Riluzole (HY-B0211), is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD) .
    Troriluzole
  • HY-107605

    iGluR Neurological Disease
    UBP296 is a potent and selective antagonist of GLUK5-containing kainate receptor in the spinal cord. UBP296 reversibly blocks ATPA-induced depressions of synaptic transmission, and affects AMPA receptor-mediated synaptic transmission directly in rat hippocampal slices .
    UBP296
  • HY-122487A

    BHV-4157 hydrochloride

    mGluR Neurological Disease
    Troriluzole hydrochloride is a third-generation peptide precursor of Riluzole (HY-B0211) and is an orally active glutamate modulator. Troriluzole hydrochloride can reduce synaptic glutamate levels and enhance the uptake of synaptic glutamate. Troriluzole hydrochloride shows potential for treating Alzheimer's disease and Generalized Anxiety Disorder (GAD) .
    Troriluzole hydrochloride
  • HY-121035

    7-Bromoindirubin-3-Oxime

    CDK GSK-3 Neurological Disease
    7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice [1].
    7BIO
  • HY-100143

    CGS 10746

    Dopamine Receptor Neurological Disease
    Pentiapine (CGS 10746) is a dopamine release inhibitor without binding to synaptic dopamine receptor sites .
    Pentiapine
  • HY-N0204

    Anemoside A3

    iGluR Others
    Pulchinenoside A is a natural triterpenoid saponin that enhances synaptic plasticity in the adult mouse hippocampus and facilitates spatial memory in adult mice.
    Pulchinenoside A
  • HY-148978

    Endogenous Metabolite Metabolic Disease
    18:0,18:1 PS sodium is a lipid component of synaptic vesicles and cholesterol, which can be used for metabolic research .
    18:0,18:1 PS sodium
  • HY-148977

    Endogenous Metabolite Metabolic Disease
    18:0,22:6 PS sodium is a lipid component of synaptic vesicles and cholesterol, which can be used for metabolic research .
    18:0,22:6 PS sodium
  • HY-136873

    Synaptic Vesicle Proteins Others
    UCB-J is a positron emission tomography (PET) radioligand for the synaptic vesicle protein 2A (SV2A) .
    UCB-J
  • HY-100407
    JNJ16259685
    2 Publications Verification

    mGluR Neurological Disease
    JNJ16259685 is a selective antagonist of mGlu1 receptor, and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with IC50 of 19 nM.
    JNJ16259685
  • HY-P3095

    Endogenous Metabolite Neurological Disease
    α-Latrotoxin, a potent neurotoxin from black widow spider venom, triggers synaptic vesicle exocytosis from presynaptic nerve terminals .
    α-Latrotoxin
  • HY-P2264

    Ephrin Receptor Inflammation/Immunology
    KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC50:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .
    KYL peptide
  • HY-P2473

    Calmodulin PKC CaMK PKA Neurological Disease
    Neurogranin (48-76), human is a dominant endogenous peptide in Alzheimer's disease (AD) brain tissue. Neurogranin (48-76) is a potential biomarker for synaptic function in AD .
    Neurogranin (48-76), human
  • HY-B0649S1

    GABA Receptor Endogenous Metabolite Neurological Disease
    Propofol-d18 is the deuterium labeled Propofol. Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission[1].
    Propofol-d18
  • HY-100842A

    GABA Receptor Neurological Disease
    (S)-3C4HPG is a metabotropic glutamate receptor antagonist, demonstrating significant potential in modulating neuronal excitability and influencing synaptic transmission.
    (S)-3C4HPG
  • HY-P10282

    CaMK Neurological Disease
    Synapsin I-(3-13), a substrate for CaMK1, is a glycoprotein. Synapsin I is a phosphoprotein that coats the cytoplasmic side of synaptic vesicles and regulates their trafficking within nerve terminals .
    Synapsin I-(3-13)
  • HY-P1054

    YNVYGIEEVKI

    PKC Neurological Disease
    pep2-EVKI (YNVYGIEEVKI) is an inhibitor peptide that selectively blocks PICK1 interactions, caused the opposite effects on synaptic AMPAR function to PICK1 expression .
    pep2-EVKI
  • HY-100785A

    γDGG acetate; γ-D-Glutamylglycine acetate

    iGluR Neurological Disease
    gamma-DGG acetate (γDGG acetate) is a competitive AMPA receptor blocker. gamma-DGG acetate is also a reversible Excitatory post-synaptic potentials (e.p.s.p.s) antagonist .
    gamma-DGG acetate
  • HY-103298

    Endogenous Metabolite Neurological Disease
    MNI-caged kainate is a photoprotected neuroactive amino acid with the activity to generate large inward currents. MNI-caged kainate can be released at the resting membrane potential of Purkinje cells and generate significant inward currents. The release of MNI-caged kainate results in approximately 40% of the current being generated through AMPA receptor activation. MNI-caged kainate is used to study fast synaptic receptor mechanisms. The photorelease time of MNI-caged kainate is in the sub-microsecond range, making it suitable for investigating the mechanisms of fast synaptic transmission .
    MNI-caged kainate
  • HY-125740

    Malvidin-3-O-glucoside chloride; Oenin chloride

    Apoptosis Inflammation/Immunology
    Malvidin-3-glucoside chloride (Malvidin-3-O-glucoside chloride), a major wine anthocyanin, is effective in promoting resilience against stress by modulating brain synaptic plasticity and peripheral inflammation .
    Malvidin-3-glucoside chloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: